NO20073465L - Benzotiazol-derivater - Google Patents

Benzotiazol-derivater

Info

Publication number
NO20073465L
NO20073465L NO20073465A NO20073465A NO20073465L NO 20073465 L NO20073465 L NO 20073465L NO 20073465 A NO20073465 A NO 20073465A NO 20073465 A NO20073465 A NO 20073465A NO 20073465 L NO20073465 L NO 20073465L
Authority
NO
Norway
Prior art keywords
benzothiazole derivatives
compounds
treatment
pharmaceutically acceptable
general formula
Prior art date
Application number
NO20073465A
Other languages
English (en)
Inventor
Alexander Alanine
Roger David Norcross
Claus Riemer
Alexander Flohr
Aubry Kern Miller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20073465L publication Critical patent/NO20073465L/no
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Foreliggende oppfinnelse angår forbindelser med den generelle formel (I) og deres farmasøytisk akseptable salter for behandling av sykdommer relatert til adenosin- reseptoren.
NO20073465A 2000-06-21 2007-07-06 Benzotiazol-derivater NO20073465L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00113219 2000-06-21
PCT/EP2001/006506 WO2001097786A2 (en) 2000-06-21 2001-06-08 Benzothiazole derivatives

Publications (1)

Publication Number Publication Date
NO20073465L true NO20073465L (no) 2002-12-12

Family

ID=8169041

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20025978A NO324635B1 (no) 2000-06-21 2002-12-12 Benzotiazolderivater, fremstilling av disse, anvendelse av slike for fremstilling av medikamenter for behandling av sykdom samt medikament inneholdende slike forbindelser
NO20073465A NO20073465L (no) 2000-06-21 2007-07-06 Benzotiazol-derivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20025978A NO324635B1 (no) 2000-06-21 2002-12-12 Benzotiazolderivater, fremstilling av disse, anvendelse av slike for fremstilling av medikamenter for behandling av sykdom samt medikament inneholdende slike forbindelser

Country Status (34)

Country Link
US (8) US6521754B2 (no)
EP (2) EP1303272B1 (no)
JP (1) JP3886897B2 (no)
KR (2) KR100571161B1 (no)
CN (1) CN1234358C (no)
AR (1) AR031244A1 (no)
AT (1) ATE385794T1 (no)
AU (2) AU2001281817B2 (no)
BR (1) BR0112395A (no)
CA (1) CA2413086C (no)
CY (1) CY1107401T1 (no)
CZ (1) CZ2003182A3 (no)
DE (1) DE60132777T2 (no)
DK (1) DK1303272T3 (no)
EC (1) ECSP024399A (no)
ES (1) ES2299504T3 (no)
HK (1) HK1058148A1 (no)
HR (1) HRP20020962A2 (no)
HU (1) HUP0301315A3 (no)
IL (2) IL153278A0 (no)
JO (1) JO2503B1 (no)
MX (1) MXPA02012596A (no)
MY (1) MY138352A (no)
NO (2) NO324635B1 (no)
NZ (1) NZ522928A (no)
PE (1) PE20020104A1 (no)
PL (1) PL207384B1 (no)
PT (1) PT1303272E (no)
RU (1) RU2251419C2 (no)
SI (1) SI1303272T1 (no)
UY (1) UY26782A1 (no)
WO (1) WO2001097786A2 (no)
YU (1) YU96502A (no)
ZA (1) ZA200209730B (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0112395A (pt) * 2000-06-21 2003-07-08 Hoffmann La Roche Derivados de benzotiazol
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
CA2467825A1 (en) * 2001-11-27 2003-06-05 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
CN1296368C (zh) * 2001-12-12 2007-01-24 弗·哈夫曼-拉罗切有限公司 用作腺苷受体调节剂的苯并噻吩化合物
US6713499B2 (en) 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
AU2003207734C1 (en) 2002-01-28 2009-10-08 Kyowa Kirin Co., Ltd. Methods of treating patients suffering from movement disorders
WO2004002531A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 血管の収縮または拡張による疾患治療剤
US6958420B2 (en) * 2002-07-19 2005-10-25 Board Of Trustees Of Michigan State University Synthesis of aminoarylboronic esters and substituted anilines from arenes via catalytic C-H activation/borylation/amination and uses thereof
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
AU2003295605A1 (en) 2002-11-19 2004-06-15 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
US7087761B2 (en) * 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
PL378343A1 (pl) * 2003-01-13 2006-03-20 F. Hoffmann-La Roche Ag Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny
US6872833B2 (en) 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
ATE407133T1 (de) * 2003-05-13 2008-09-15 Hoffmann La Roche 2-imidazo-benzothiazole als adenosin-rezeptor liganden
DK1636223T3 (da) * 2003-05-19 2008-06-23 Hoffmann La Roche Benzothiazolderivater som adenosinreceptorligander
AU2004241720B2 (en) * 2003-05-21 2008-11-06 F. Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine A2A receptor
CA2527174C (en) * 2003-05-30 2014-03-25 F.Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor
NZ544674A (en) * 2003-07-10 2009-03-31 Achillion Pharmaceuticals Inc Substituted arylthiourea derivatives useful as inhibitors of viral replication
DK1648879T3 (da) * 2003-07-24 2009-02-23 Euro Celtique Sa Heteroaryl-tetrahydropyridyl-forbindelser, der er anvendelige til behandling eller forebyggelse af smerte
NZ619746A (en) 2003-08-06 2014-05-30 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
CA2539314A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
JP4668265B2 (ja) * 2004-05-24 2011-04-13 エフ．ホフマン−ラ ロシュ アーゲー ４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド
KR100834179B1 (ko) * 2004-05-24 2008-05-30 에프. 호프만-라 로슈 아게 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드
WO2006008041A1 (en) * 2004-07-22 2006-01-26 F. Hoffmann-La Roche Ag Benzothiazole derivatives
MX2007000635A (es) * 2004-07-22 2007-03-07 Hoffmann La Roche Benzotiazoles sustituidos.
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
JP4633123B2 (ja) 2004-11-05 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー イソニコチン酸誘導体の製造方法
CN101180299B (zh) 2005-03-23 2010-12-15 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的乙炔基-吡唑并嘧啶衍生物
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
EP1934214B1 (en) 2005-09-27 2010-04-07 F.Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2007098826A2 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
TWI425917B (zh) 2006-04-21 2014-02-11 Senomyx Inc 包含高度鮮味風味劑之可食用組合物及其製造方法
US7429589B2 (en) 2006-04-27 2008-09-30 Hoffmann-La Roche Inc. Mono-nitration of aromatic compounds via nitrate salts
AU2007253485B2 (en) * 2006-05-18 2010-07-08 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine A2B receptor antagonists
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0612428D0 (en) * 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
WO2008077809A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Process for the manufacture of 7-oxa-bicyclo derivatives
EP2139907B1 (en) 2007-02-14 2013-08-14 Basf Se Electroluminescent metal complex
PE20130325A1 (es) 2007-04-27 2013-03-18 Purdue Pharma Lp Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1
WO2009015236A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
US7913765B2 (en) * 2007-10-19 2011-03-29 Baker Hughes Incorporated Water absorbing or dissolving materials used as an in-flow control device and method of use
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR101064258B1 (ko) * 2008-12-29 2011-09-14 한국과학기술연구원 벤조아릴우레이도 화합물, 및 이를 함유하는 퇴행성 뇌질환예방 또는 치료용 조성물
US8168785B2 (en) 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
WO2010150927A1 (en) * 2009-06-25 2010-12-29 Sk Holdings Co., Ltd. Pharmaceutical composition for prevention and treatment of cancer diseases comprising benzamide derivatives
RU2455293C2 (ru) * 2010-09-15 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) N-(2-бензотиазолил)амид 3-бром-2,4-диоксо-4-(4-метоксифенил)бутановой кислоты, обладающий гипогликемической активностью
RU2448100C1 (ru) * 2010-09-24 2012-04-20 Татьяна Николаевна Иванова Производные 2-аминобензотиазола, обладающие противогипоксической активностью, и способ их использования
JP5769326B2 (ja) * 2010-10-19 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｈｏキナーゼ阻害薬
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
UA113288C2 (xx) 2011-06-22 2017-01-10 Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN103772376B (zh) * 2012-10-24 2017-01-11 中国医学科学院医药生物技术研究所 取代的苯并-1,3-杂唑类化合物、其制备方法及用途
US9988374B2 (en) 2014-08-11 2018-06-05 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AU2015374231B2 (en) * 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
WO2017066225A1 (en) * 2015-10-14 2017-04-20 Texas Tech University System Pharmacoperones of the v2 receptor
EP3512602B1 (en) * 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
AU2018309265B2 (en) * 2017-08-01 2022-06-02 Merck Patent Gmbh Thiazolopyridine derivatives as adenosine receptor antagonists
RU2748993C1 (ru) * 2017-09-28 2021-06-02 СиСТОУН ФАРМАСЬЮТИКАЛС (СУЧЖОУ) КО., ЛТД. Производное с конденсированным кольцом в качестве ингибитора рецептора a2a
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
CA3162227A1 (en) * 2019-12-16 2021-06-24 David Scott Grierson Antiviral compounds, compositions and methods of use
WO2021247921A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Benzothiazole compounds and uses thereof
CN116829542A (zh) * 2021-01-29 2023-09-29 韩国化学研究院 苯并噻唑及苯并咪唑衍生物、药学上可接受的盐、其制备方法以及包含其作为活性成分的药物组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
GB1318291A (en) * 1970-04-15 1973-05-23 Shell Int Research Carboxamide derivatives and fungicidal compositions containing them
LU63457A1 (no) * 1970-07-06 1971-11-12
JPS5516147B2 (no) * 1971-12-24 1980-04-30
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de) * 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
US4471957A (en) * 1979-12-03 1984-09-18 Baltimore Therapeutic Equipment Company Method and apparatus for rehabilitation of damaged limbs
CA1153867A (en) 1980-05-16 1983-09-20 Michael A. M. Boersma Process for the preparation of crystalline silicates, crystalline silicates so prepared and process for carrying out catalytic reactions
KR930005004B1 (ko) * 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
EP0300688A1 (en) * 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5348519A (en) * 1988-02-04 1994-09-20 Loredan Biomedical, Inc. Exercise and diagnostic apparatus and method
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JPH0667923B2 (ja) 1989-05-11 1994-08-31 東洋紡績株式会社 新規なベンゾチアゾール誘導体
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
DE59005183D1 (de) 1989-11-10 1994-05-05 Agrolinz Agrarchemikalien Verfahren zur Herstellung reiner, unsymmetrisch disubstituierter Harnstoffe.
US5142910A (en) * 1990-06-27 1992-09-01 Occupational Orthopaedic Systems, Inc. Dynamic physiological function testing apparatus and method
ATE132486T1 (de) * 1990-10-15 1996-01-15 Pfizer Pyrrolidin-dionderivate
US5275045A (en) * 1991-03-07 1994-01-04 Isotechnologies, Inc. Apparatus and method for use in assessing the lifting capability of a human subject
CN1038586C (zh) * 1991-05-01 1998-06-03 大制药株式会社 吡嗪衍生物的制备方法
EP0604657B1 (en) * 1992-05-21 2000-01-12 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
US5312107A (en) * 1993-05-13 1994-05-17 Kordun, Ltd. Golf club swing training and exercise device
JPH0725858A (ja) * 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
JPH0940646A (ja) * 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd ベンゼン縮合環誘導体又はその塩
FR2753970B1 (fr) 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
TR200001312T2 (tr) * 1997-11-10 2000-09-21 Bristol-Myers Squibb Company Benzotiyazol protein tirozin kinaz önleyicileri.
AU1924099A (en) * 1997-12-18 1999-07-05 Lyonnaise Industrielle Pharmaceutique (Lipha) Piperazine derivatives useful as hypoglycemic agents
CA2318969A1 (en) * 1998-01-23 1999-07-29 Mikhail F. Gordeev Oxazolidinone combinatorial libraries, compositions and methods of preparation
CN1325397A (zh) 1998-09-30 2001-12-05 纽罗根公司 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP2002533453A (ja) * 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー Ｘａ因子のインヒビターとしてのヘテロ芳香族アミド
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
BR0112395A (pt) * 2000-06-21 2003-07-08 Hoffmann La Roche Derivados de benzotiazol
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives

Also Published As

Publication number Publication date
NZ522928A (en) 2005-05-27
NO20025978L (no) 2002-12-12
US6521754B2 (en) 2003-02-18
CA2413086C (en) 2011-06-28
US20020045615A1 (en) 2002-04-18
ECSP024399A (es) 2003-02-06
IL153278A0 (en) 2003-07-06
ZA200209730B (en) 2004-03-01
CA2413086A1 (en) 2001-12-27
EP1303272A2 (en) 2003-04-23
EP1797878A2 (en) 2007-06-20
JP2003535887A (ja) 2003-12-02
PE20020104A1 (es) 2002-02-16
US20050026906A1 (en) 2005-02-03
US20060003986A1 (en) 2006-01-05
ES2299504T3 (es) 2008-06-01
AU8181701A (en) 2002-01-02
EP1797878A3 (en) 2010-01-20
WO2001097786A3 (en) 2002-12-12
WO2001097786A2 (en) 2001-12-27
US7317007B2 (en) 2008-01-08
KR20050043912A (ko) 2005-05-11
CY1107401T1 (el) 2012-12-19
CZ2003182A3 (cs) 2003-06-18
BR0112395A (pt) 2003-07-08
HRP20020962A2 (en) 2005-02-28
ATE385794T1 (de) 2008-03-15
EP1303272B1 (en) 2008-02-13
CN1234358C (zh) 2006-01-04
US6835732B2 (en) 2004-12-28
US6963000B2 (en) 2005-11-08
US20080125419A1 (en) 2008-05-29
DE60132777D1 (de) 2008-03-27
HUP0301315A3 (en) 2007-10-29
IL153278A (en) 2012-12-31
JO2503B1 (en) 2009-10-05
DE60132777T2 (de) 2009-02-12
KR100571161B1 (ko) 2006-04-17
PT1303272E (pt) 2008-04-14
PL360697A1 (en) 2004-09-20
CN1437471A (zh) 2003-08-20
DK1303272T3 (da) 2008-05-26
AU2001281817B2 (en) 2005-11-24
US20030176695A1 (en) 2003-09-18
HK1058148A1 (en) 2004-05-07
AR031244A1 (es) 2003-09-17
PL207384B1 (pl) 2010-12-31
JP3886897B2 (ja) 2007-02-28
MXPA02012596A (es) 2003-04-10
YU96502A (sh) 2006-01-16
US20030125318A1 (en) 2003-07-03
SI1303272T1 (sl) 2008-06-30
NO20025978D0 (no) 2002-12-12
KR100526487B1 (ko) 2005-11-08
US20080108809A1 (en) 2008-05-08
HUP0301315A2 (hu) 2003-08-28
NO324635B1 (no) 2007-11-26
UY26782A1 (es) 2001-12-28
MY138352A (en) 2009-05-29
US20100075959A1 (en) 2010-03-25
RU2251419C2 (ru) 2005-05-10
KR20030019446A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
NO20073465L (no) Benzotiazol-derivater
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20054848L (no) Substituerte p-diaminobenzenderivater
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
JO2282B1 (en) Oxazole derivatives
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
NO20053748L (no) Pyrrolopyridazinderivater.
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20055562L (no) Substituerte indolin- og indolderivater
NO20051263L (no) Ny anvendelse av benzotiazolderivater
NO20081844L (no) Terapeutiske forbindelser
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
ATE384058T1 (de) Thiazolderivate
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
NO20062599L (no) Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser
NO20054721L (no) Substituerte anilinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application